Login
$TPST
$0.51 -$0.00 (0.16%) Close

Company Executives

$TPST Management Team

Mr. Nicholas Maestas

Chief Financial Officer

Head - Corporate Strategy

Corporate Secretary

Age 46
Compensation $622.1K USD
Sex Male

Mr. Stephen Brady

Chairman of the Board

Age 55
Compensation $1.872M USD
Sex Male

Dr. Matthew Angel

President

Chief Executive Officer

Director

Age 45
Compensation -
Sex Male

Dr. Samuel Whiting

Executive Vice President

Chief Medical Officer

Age 60
Compensation $1.063M USD
Sex Male
Directors
5
serving now
Independent
0 of 1
stated in the proxy; 4 not stated
Average tenure
0.0 years
from year joined
CEO also chairs the board
Yes
Matthew Angel
Director Age On board Independent Committees Other public boards Pay Source
John David Yee
63 2026
0 years
Not stated None stated None stated Not stated
William Drake Richey
44 2026
0 years
Not stated None stated None stated Not stated
Nancy Freda-Smith
54 2026
0 years
Not stated
Audit · Chair
None stated Not stated
John Frederick
63 2026
0 years
Not stated None stated None stated Not stated
Matthew Angel
45 2026
0 years
Not independent None stated None stated Paid as CEO

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Erigen LLC
affiliate of Factor, with members Dr. Angel and Lotus Capital BVI Limited
8,268,495 shares of our common stock

Asset Purchase Agreement under which Erigen sold assets to the Company in exchange for shares of common stock

Factor
affiliate of Dr. Angel, provided Funding Commitment under the Asset Purchase Agreement
Up to a maximum of $20.0 million

Factor funding commitment to provide financial support to the Company

With Company Open in proxy
Erigen LLC
affiliate of Factor
Up to $80 million in total upon achievement of certain development milestones

Exclusive license and collaboration agreement assigned to the Company, with milestone and royalty payments

With Novatim Immune Therapeutics Open in proxy
Factor
affiliate of Dr. Angel; Factor Bioscience Limited is a wholly owned subsidiary of Factor
Up to $40 million in total upon achievement of certain development milestones

Amended and restated license and collaboration agreement assigned to the Company, with milestone and royalty payments

With Factor Bioscience Limited Open in proxy
Factor
Amount not stated

Amended and restated master services agreement under which Factor provides services on a fee-for-services basis

With Factor Open in proxy
Factor
Amount not stated
through March 31, 2027

Work Order No. 1 for research and development services through March 31, 2027, with fees waived in part

With Factor Open in proxy
Factor
affiliate of Dr. Angel; Dr. Angel is majority owner and chairman of Factor Bioscience LLC
$5.0 million per year
per year

2026 Master Services Agreement under which Factor provides research and development services for fees

With Tempest Open in proxy
Factor Bioscience Inc.
entity of which Dr. Angel is majority stockholder and Chairman of the Board
$0.5 million
2026

Sale of shares and warrants to Factor in the private placement

With Company Open in proxy
Erigen LLC
affiliate of Factor
Approximately $0.4 million

Company settled Erigen legal fees incurred before the Erigen closing with WSGR, recorded as G&A expense

With Wilson Sonsini Goodrich & Rosati Open in proxy
Andrew Fang
son of Bangxia Yang, the beneficial owner of Lotus, a greater than 5% holder
Up to a maximum aggregate amount of $720,000 per year
per year

Professional Services Agreement under which YQ provides business development and corporate development services at hourly rates

With YQ Advisors Limited Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support